0000950170-24-077522.txt : 20240625 0000950170-24-077522.hdr.sgml : 20240625 20240625200030 ACCESSION NUMBER: 0000950170-24-077522 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240621 FILED AS OF DATE: 20240625 DATE AS OF CHANGE: 20240625 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brown Ryan Edward CENTRAL INDEX KEY: 0001848718 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 241070352 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: STE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 930797222 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-274-4000 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 4 1 ownership.xml 4 X0508 4 2024-06-21 0000873303 Sarepta Therapeutics, Inc. SRPT 0001848718 Brown Ryan Edward 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02124 false true false false EVP, General Counsel true Common Stock 2024-06-21 4 M false 6250 A 34938.00 D Common Stock 2024-06-24 4 F false 2352 164.64 D 32586.00 D Common Stock 2024-06-25 4 M false 23500 62.77 A 56086.00 D Common Stock 2024-06-25 4 S false 7644 158.07 D 48442.00 D Common Stock 2024-06-25 4 S false 2200 159.14 D 46242.00 D Common Stock 2024-06-25 4 S false 975 160.31 D 45267.00 D Common Stock 2024-06-25 4 S false 4168 161.82 D 41099.00 D Common Stock 2024-06-25 4 S false 17581 162.65 D 23518.00 D Common Stock 2024-06-25 4 S false 3840 163.53 D 19678.00 D Common Stock 2024-06-25 4 S false 2549 164.52 D 17129.00 D Performance Stock Units 2024-06-21 4 A false 5500 0 A Common Stock 5500 5500 D Performance Stock Units 2024-06-21 4 A false 6250 0 A Common Stock 6250 6250 D Performance Stock Units 2024-06-21 4 M false 6250 0 D Common Stock 6250 0 D Stock Option (right to buy) 62.77 2024-06-25 4 M false 23500 0 D 2019-02-28 2028-02-28 Common Stock 23500 0 D Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 1, 2024. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.58 to $158.52, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.67 to $159.66, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.71 to $160.69, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.04 to $162.02, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.12 to $163.09, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.19 to $163.98 inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Represents the number of shares earned under a PSU award granted to the Reporting Person on March 7, 2022. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 7, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date. /s/ Ryan Brown 2024-06-25